Xencor (NASDAQ:XNCR) Shares Climb 4.6% – Should You Buy?

Xencor, Inc. (NASDAQ:XNCR) shares rose 4.6% during mid-day trading on Monday. The company traded as high as $24.66 and last traded at $24.8920. 290,326 shares traded hands during trading, a decline of 69% from the average session volume of 949,940 shares. The stock had previously closed at $23.80.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on XNCR shares. Barclays boosted their price objective on shares of Xencor from $27.00 to $35.00 and gave the company an “overweight” rating in a research report on Friday, September 11th. JPMorgan Chase & Co. increased their price objective on Xencor from $14.00 to $21.00 and gave the stock a “neutral” rating in a research note on Thursday, September 3rd. Royal Bank Of Canada raised their price objective on Xencor from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Cantor Fitzgerald upped their price target on shares of Xencor from $43.00 to $44.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Finally, Raymond James Financial increased their price objective on shares of Xencor from $40.00 to $46.00 and gave the company a “strong-buy” rating in a research note on Tuesday, September 1st. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.38.

Xencor Price Performance

The company’s fifty day simple moving average is $23.78 and its 200-day simple moving average is $16.66. The firm has a market capitalization of $1.90 billion, a PE ratio of -11.77 and a beta of 0.88.

Xencor (NASDAQ:XNCR) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.51. The firm had revenue of $51.22 million for the quarter, compared to the consensus estimate of $18.89 million. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The firm’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.41) EPS. As a group, equities research analysts anticipate that Xencor, Inc. will post -3.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xencor

A number of large investors have recently made changes to their positions in XNCR. Seven Fleet Capital Management LP acquired a new stake in Xencor during the 2nd quarter valued at approximately $7,828,524,000. BlackRock Inc. purchased a new position in Xencor during the second quarter valued at approximately $219,785,000. Primecap Management Co. CA acquired a new position in Xencor in the second quarter valued at approximately $163,919,000. BVF Inc. IL boosted its position in Xencor by 160.3% in the 4th quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock worth $109,217,000 after purchasing an additional 4,393,579 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in Xencor by 2.8% in the 4th quarter. Legal & General Group Plc now owns 1,308,088 shares of the biopharmaceutical company’s stock worth $20,027,000 after purchasing an additional 35,088 shares in the last quarter.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company that develops engineered antibodies and cytokine therapeutics for the treatment of cancer, autoimmune diseases and other serious medical conditions. The company’s platform is designed to modify antibody properties, including immune-system activation, half-life and biological activity, to create differentiated therapeutic candidates.

Xencor’s proprietary XmAb technology supports its internal research programs and collaborations with other biopharmaceutical companies.